Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains widely pandemic around the world. Animal models that are sensitive to the virus are therefore urgently needed to evaluate potential vaccines and antiviral agents; however, SARS-CoV-2...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2023-06, Vol.11 (7), p.1133
Main Authors: Wu, Xi, Fang, Nana, Liang, Ziteng, Nie, Jianhui, Lang, Sen, Fan, Changfa, Liang, Chunnan, Huang, Weijin, Wang, Youchun
Format: Article
Language:English
Subjects:
Animal models
Antiviral agents
Bioluminescence
Biosafety
Care and treatment
Communication
Coronaviruses
COVID-19
Effectiveness
in vivo bioluminescent
Infections
Intranasal administration
Laboratory animals
Medical care
Medical imaging
Monoclonal antibodies
mouse model
Pandemics
Patients
Plasmids
Proteins
Quality management
Reagents
Reporter gene
SARS-CoV-2 pseudovirus
Severe acute respiratory syndrome coronavirus 2
Tropism
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains widely pandemic around the world. Animal models that are sensitive to the virus are therefore urgently needed to evaluate potential vaccines and antiviral agents; however, SARS-CoV-2 requires biosafety level 3 containment. To overcome this, we developed an animal model using the intranasal administration of SARS-CoV-2 pseudovirus. As the pseudovirus contains the firefly luciferase reporter gene, infected tissues and the viral load could be monitored by in vivo bioluminescent imaging. We used the model to evaluate the protective efficacy of monoclonal antibodies and the tissue tropism of different variants. The model may also be a useful tool for the safe and convenient preliminary evaluation of the protective efficacy of vaccine candidates against SARS-CoV-2, as well as the treatment efficacy of anti-viral drugs.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11071133